PES2020-Prosj.etabl.støtte H2020
A feasibility study on the development of Asacor for emergency use to reduce the risk of vascular mortality in patients with suspected AMI
Asamedic AS, a Norwegian biotech company, is developing Asacor, which is an innovative, soluble formulation of acetylsalicylic acid (ASA), i.e. a drug which is supposed to reduce the risk of vascular mortality in patients with a suspected acute myocardial infarction (AMI). Asacor consists of a d...